Gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804): a multicentre, double-blind randomised phase 3 trial
The Lancet Oncology,  Clinical Article

Zhang L et al. – Maintenance treatment with gefitinib significantly prolonged progression-free survival compared with placebo in patients from east Asia with advanced NSCLC who achieved disease control after first-line chemotherapy.

Methods

  • Patients were aged 18 years or older, were of east Asian ethnic origin, had a life expectancy of more than 12 weeks, histologically or cytologically confirmed stage IIIb or IV NSCLC, a WHO performance status of 0—2, and had completed four cycles of first-line platinum-based doublet chemotherapy without disease progression or unacceptable toxic effects.
  • Between Sept 28, 2008 and Aug 11, 2009, 296 patients were randomly assigned 1:1 to receive either gefitinib (250 mg per day orally) or placebo (orally) within 3—6 weeks after chemotherapy until progression or unacceptable toxic effects.
  • Randomisation was done via an interactive web response system with computer-generated randomisation codes.
  • Our primary endpoint was progression-free survival assessed in the intention-to-treat population.

Results
  • Progression-free survival was significantly longer with gefitinib (n=148) than with placebo (148) (median progression-free survival 4·8 months [95% CI 3·2—8·5] vs 2·6 months [1·6—2·8]; hazard ratio [HR] 0·42, 95% CI 0·33—0·55; p<0·0001).
  • Adverse events occurred more frequently with gefitinib than with placebo; the most common adverse events of any grade were rash (73 [50%] of 147 in the gefitinib group vs 14 [9%] of 148 in the placebo group), diarrhoea (37 [25%] vs 13 [9%]), and alanine aminotransferase increase (31 [21%] vs 12 [8%]).
  • The most commonly reported grade 3 or 4 adverse event was alanine aminotransferase increase (3 [2%] of 147 in the gefitinib group, none of 148 in the placebo group).
  • Ten of 147 (7%) patients given gefitinib and five of 148 (3%) patients given placebo had serious adverse events.
  • Three deaths were thought to be related to treatment with gefitinib: one from interstitial lung disease; one from lung infection; and one from pneumonia.

Please login or register to follow this author.
Are you sure you want to Unfollow this Author?
► Click here to access PubMed, Publisher and related articles...
<< Previous Article | Next Article >>

Your Unread Messages in Pharmacy

See All >> Messages include industry-sponsored communications and special communications from MDLinx

Most Popular Pharmacy Articles

1 Precautionary labelling of foods for allergen content: Are we ready for a global framework? Full Text World Allergy Organization Journal, May 8, 2014    Free full text    Review Article

2 A pilot study to assess feasibility of value based pricing in Cyprus through pharmacoeconomic modelling and assessment of its operational framework: Sorafenib for second line renal cell cancer Full Text Cost Effectiveness and Resource Allocation, May 5, 2014    Free full text

3 Vancomycin, metronidazole, or tolevamer for clostridium difficile infection: Results from two multinational, randomized, controlled trials Clinical Infectious Diseases, June 6, 2014    Clinical Article

4 Maternal high-dose folic acid during pregnancy and asthma medication in the offspring Pharmacoepidemiology and Drug Safety, June 23, 2014    Clinical Article

5 Reprint of “Heated vegetable oils and cardiovascular disease risk factors” Vascular Pharmacology, June 4, 2014    Review Article

6 Diuretics in the treatment of hypertension. Part 2: loop diuretics and potassium-sparing agents Expert Opinion on Pharmacotherapy, March 17, 2014    Review Article

7 Effects of one-time apple juice ingestion on the pharmacokinetics of fexofenadine enantiomers European Journal of Clinical Pharmacology, June 12, 2014    Clinical Article

8 Cost-effectiveness of cranberries vs antibiotics to prevent urinary tract infections in premenopausal women: a randomized clinical trial PLOS ONE, April 15, 2014    Review Article

9 Economic evaluation of warfarin, dabigatran, rivaroxaban, and apixaban for stroke prevention in atrial fibrillation PharmacoEconomics, April 9, 2014    Clinical Article

10 The effectiveness of metoprolol versus atenolol on prevention of all-cause and cardiovascular mortality in a large Chinese population: A cohort study International Journal of Cardiology, June 27, 2014    Clinical Article

11 Prasugrel versus clopidogrel in patients with ST-segment elevation myocardial infarction according to timing of percutaneous coronary intervention JACC Cardiovascular Interventions, June 20, 2014    Clinical Article

12 New oral anticoagulants in patients with nonvalvular atrial fibrillation: a review of pharmacokinetics, safety, efficacy, quality of life, and cost effectiveness Full Text Drug Design, Development and Therapy, June 18, 2014    Free full text    Review Article

13 Efficacy of nebulised budesonide versus oral prednisolone in acute severe asthma The Indian Journal of Pediatrics, June 11, 2014    Clinical Article

14 HIV risk reduction with buprenorphine-naloxone or methadone: Findings from a randomized trial Journal of Acquired Immune Deficiency Syndromes, June 19, 2014    Clinical Article

15 Beyond statins: new lipid lowering strategies to reduce cardiovascular risk Current Atherosclerosis Reports, May 21, 2014    Review Article    Clinical Article

16 Aspirin desensitization in patients with aspirin-induced and aspirin-tolerant asthma: A double-blind study The Journal of Allergy and Clinical Immunology, June 13, 2014    Clinical Article

17 The administration of a loading dose of aspirin to patients presenting with acute myocardial infarction while receiving chronic aspirin treatment reduces thromboxane A2-dependent platelet reactivity Platelets, June 10, 2014    Clinical Article

18 Warfarin dosing and body mass index Annals of Pharmacotherapy, April 21, 2014    Clinical Article

19 Novel approaches to the development of targeted therapeutic agents for systemic lupus erythematosus Journal of Autoimmunity , June 24, 2014    Review Article

20 Single-dose intra-articular bupivacaine versus morphine after arthroscopic knee surgery: A meta-analysis of randomized-controlled studies The Clinical Journal of Pain, June 10, 2014    Clinical Article

Indexed Journals in Pharmacy: Expert Opinion in Pharmacotherapy, Formulary, U.S.Pharmacistmore

Register now to view all the MDLinx contents (FREE)!

  • Stay current on the latest literature, research and clinical news
  • Get special communications and offers from MDLinx and our sponsors
  • Receive invitations to paid market research
View Samples and Register

Connect with us, stay current.

Receive the latest mecial news
updates for free via email

Sign up!

Subscribe to our free RSS feeds:

Get the latest news in your specialty automatically added to your newsreader or your personal My Yahoo!, Google, My MSN or My AOL page. Learn More

Close